ClinicalTrials.gg
CompletedNCT00071461BUILD 1Updated Feb 24, 2012

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2/3 interventional study of bosentan and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Actelion. Completed at 29 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-24.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
53rd of 188
158 · median 61
Started
2003
with 6 others
Phase 2/3
2 of 236
none open now
Registered
5th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 53rd largest by enrollment of the 188 interventional ones that give a count, is one of 7 that started in 2003, is one of 2 in phase 2/3, and was the 5th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis.

Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available.

The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF.

It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic pulmonary fibrosis
  • Interstitial lung disease
  • Bosentan
  • BUILD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients over 18 years of age.

    • Women must be either (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.
    • Women of must have a negative pre-treatment pregnancy test and use a reliable method of during study treatment and for at least 3 months after study treatment termination.
  2. IPF proven diagnosis \< 3 years documented according to ATS/ERS international multidisciplinary consensus, with or without surgical (thoracoscopic or open) chest lung
  3. Duration of illness ≥ 3 months.
  4. Six-minute walk test distance (limited by dyspnea) ≥ 150 meters and \< 500 meters
  5. Patients who have signed the form prior to initiation of any study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Interstitial lung disease due to conditions other than IPF, including but not limited to radiation, sarcoidosis, pneumonitis, bronchiolitis obliterans with organizing pneumonia, and cancer.
  2. History of environmental exposure known to cause pulmonary fibrosis (drugs, asbestos, beryllium, radiation, domestic birds, etc.).
  3. Severe concomitant illness limiting (\< 1 year).
  4. FVC ≥ 90% predicted.
  5. Severe restrictive lung disease: FVC \< 50% predicted or FVC \< 1.2 l, or DLco \< 30% predicted or residual volume ≥ 120% predicted.
  6. Severe obstructive lung disease: /FVC\< 0.65.
  7. Documented improvement of patient's condition within 12 months prior to randomization with or without IPF-specific therapy (e.g., , , cytotoxic or antifibrotic drugs, TNFa blocker, interferon g).
  8. Recent pulmonary or upper respiratory track infection (within 4 weeks of randomization).
  9. PaO2 \< 55 mm Hg (sea level) or 50 mm Hg (altitude) at rest on room air.
  10. Echocardiographic evidence of severe pulmonary hypertension (PH): systolic pulmonary pressure ≥ 50 mm Hg or tricuspid regurgitation velocity ≥ 3.2 m/sec (unless severe PH is invalidated by a right heart catheterization). If the pulmonary pressure is not quantifiable, presence of significant right ventricular enlargement or hypertrophy or right ventricular dysfunction.
  11. Severe chronic heart failure, e.g., class III or IV and/or \< 25%.
  12. Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements, e.g., the 6MWT or the PFTs.

    (e.g., angina pectoris, intermittent claudicating, chronic arthritis).

  13. Baseline values of liver transaminases, i.e., (AST) and/or alanine aminotransferases (ALT) > 3 times the ranges.
  14. Moderate to severe hepatic impairment, i.e., Class B or C.
  15. Serum creatinine ≥ 2.5 mg/dl (221 mmol/l) or dialysis.
  16. concentration \< 75% the lower limit of normal ranges.
  17. Systolic blood pressure \< 85 mm Hg.
  18. Pregnancy or breast-feeding.
  19. Current drug or alcohol dependence.
  20. Smoker (≥ 5 cigarettes per day) or former smoker (≥ 5 cigarettes per day) having stopped less than 6 months prior to randomization.
  21. Recently started (\< 8 weeks from Screening visit) or planned cardio-pulmonary rehabilitation program based on exercise.
  22. Treatment with oral corticosteroids (> 15 mg/day prednisone or equivalent), immunosuppressive, cytotoxic or antifibrotic drugs such as TNF alpha blocker, or interferon gamma within 4 weeks of randomization.within 4 weeks of randomization.
  23. Treatment with glibenclamide (glyburide), cyclosporine A or tacrolimus within 1 weeks of randomization.
  24. Treatment with an endothelin receptor antagonist within 3 months of randomization.
  25. Treatment within 3 months of randomization or planned treatment with another drug.
  26. Known hypersensitivity to bosentan or any of the .
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    1

    Initial dose: 62.5 mg b.i.d. for 4 weeks. * Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated). * body weight \< 40 kg (90 lb): 62.5 mg b.i.d.

    Drug: bosentan

  • Placebo comparator
    2

    Initial dose: 62.5 mg b.i.d. for 4 weeks. * Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated). * body weight \< 40 kg (90 lb): 62.5 mg b.i.d.

    Drug: Placebo

Interventions

  • Initial dose: 62.5 mg b.i.d. for 4 weeks. * Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated). * body weight \< 40 kg (90 lb): 62.5 mg b.i.d.

    Also known as: Tracleer

  • DrugPlacebo

    Initial dose: 62.5 mg b.i.d. for 4 weeks. * Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated). * body weight \< 40 kg (90 lb): 62.5 mg b.i.d.

06

What researchers measure

Primary outcomes

  1. Change in 6-minute walk distance

    Time frame: Baseline to End-of-Period 1

Secondary outcomes

  1. Death or treatment failure

    Time frame: Up to End-of-Period 1

07

Study locations

29 sites
  • University of Alabama at Birmingham - Pulmonary Division
    Birmingham, Alabama 35294, United States
  • David Geffen School of Medicine at UCLA - Division of Pulmonary and Critical Care Medicine
    Los Angeles, California 90024, United States
  • UCSD Medical Center
    San Diego, California 92103, United States
  • University of California - Ambulatory Care Center
    San Francisco, California 94143, United States
  • National Jewish Medical and Research Center
    Denver, Colorado 80204, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • University of Iowa Hospitals & Clinics - Department of Internal Medicine
    Iowa city, Iowa 52242, United States
  • University of Michigan Health System - Division of Pulmonary & Critical Care Medicine
    Ann Arbor, Michigan 48109, United States
  • Mayo Medical School - Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Washington - Division of Pulmonary & Critical Care Medicine
    Seattle, Washington 98195, United States
  • University of Wisconsin Hospitals & Clinics - Section of Pulmonary and Critical Care Medicine
    Madison, Wisconsin 53792, United States
  • University of British Columbia - St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Rosedale Medical Center
    Toronto, Ontario M4X 1W4, Canada
  • Notre-Dame Hospital - Clinique du Thorax
    Montreal, Quebec H2L 4M1, Canada
  • Hôpital Avicenne - Université de Paris
    Bobigny, France
  • Médecine Spécialisée Aigüe - CHU Grenoble
    Grenoble, 38043, France
  • Hôpital Louis Pradel
    Lyon, 69000, France
  • Abt. Pneumologie Medizinische Klinik Universitätsklinikum Freiburg
    Freiburg, Germany
  • Klinik Löwenstein gGmbH
    Loewenstein, Germany
  • Medizinische Klinik und Poliklinik I Klinikum der Universität München
    Munchen, Germany
  • Sheba Medical Center
    Tel-Hashomer, Israel
  • Section of Respiratory Diseases - Policlinico Le Scotte - Siena University
    Siena, Italy
  • Inselspital
    Bern, Switzerland
  • Royal Brompton Hospital
    London, United Kingdom
08

References and documents

Publications

  • Raghu G, King TE Jr, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, Swigris J. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J. 2010 Jan;35(1):118-23. doi: 10.1183/09031936.00188108. Epub 2009 Aug 13. PubMed 19679600 ↗
  • King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81. doi: 10.1164/rccm.200705-732OC. Epub 2007 Sep 27. PubMed 17901413 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Sep 2005 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2003
First posted
Oct 24, 2003
Start
Aug 2003
Primary completionActual
Sep 2005
CompletionActual
May 2010
Results delay requested
Feb 11, 2010
Last update
Feb 24, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00071461
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Oct 24, 2003
Start date
Aug 2003
Primary completion
Sep 2005
Completion
May 2010
Last update
Feb 24, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion